Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Disease research sits at the center of this dementia and brain health question.
Recent genome-wide studies have uncovered 91 genetic regions associated with Alzheimer’s disease and related dementias—16 more than previously known—marking a significant expansion of our understanding of how genetics influences dementia risk. An international research collaboration analyzing data from nearly 1 million individuals, including over 128,000 Alzheimer’s disease cases, has created the most comprehensive genetic map of Alzheimer’s disease to date. These findings provide concrete answers to questions researchers have asked for years: exactly which genes matter, how strongly they influence disease development, and whether we can use genetic information to predict who will develop severe brain changes.
The discovery process involved examining the complete genomes of hundreds of thousands of people, identifying genetic variations that appear more frequently in those who develop Alzheimer’s disease compared to those who remain cognitively healthy. This approach, called genome-wide association studies (GWAS), doesn’t just identify individual genes—it reveals patterns across the entire genetic landscape, showing how multiple genes working together create a person’s overall genetic risk for disease. These new findings are particularly important because they move beyond studying only people of European ancestry, expanding to include understudied populations where genetic variants may operate differently.
Table of Contents
- What Are Genome-Wide Association Studies and How Do They Reveal Alzheimer’s Genetic Risk?
- The 91 Genetic Loci Discovery—What the New Risk Regions Tell Us About Alzheimer’s
- How Immune Cells and Lipid Metabolism Emerge as Key Players in Genetic Risk
- Understanding Polygenic Risk Scores—From Genetic Data to Individual Prediction
- The APOE Gene and Beyond—Why Some Genetic Risk Factors Matter More Than Others
- Multi-Ancestry Research—Moving Beyond European Ancestry Studies
- Future Directions—From Genetic Discovery to Clinical Application
- Conclusion
What Are Genome-Wide Association Studies and How Do They Reveal Alzheimer’s Genetic Risk?
Genome-wide association studies represent a fundamental shift in how researchers approach understanding complex diseases like Alzheimer’s. Rather than looking at single genes in isolation, GWAS examines millions of genetic variants across the entire genome, comparing people with disease to those without. The method works like a massive matching game—researchers line up genetic sequences from thousands of individuals side by side and look for positions where people with Alzheimer’s disease consistently have different genetic variants compared to healthy controls. This statistical approach can identify genetic risk factors even when individual variants have small effects on disease development.
The scale of the recent research exemplifies how this method has evolved. The 2026 meta-analysis combined genetic data from nearly 1 million individuals, providing statistical power that previous studies simply lacked. By examining such large populations, researchers could confidently identify genetic regions that might contribute only modestly to disease risk—variants that would be invisible in smaller studies. This is comparable to how weather patterns become clear only when examining decades of data; with just a few years of observations, random variation can obscure true trends. The dramatic expansion from approximately 75-90 known genetic loci to 91 loci represents not just incremental progress but a substantially more complete picture of how genetics influences Alzheimer’s disease development.
The 91 Genetic Loci Discovery—What the New Risk Regions Tell Us About Alzheimer’s
The identification of 91 genetic regions associated with Alzheimer’s disease signals a major shift in genetic research, but the practical importance lies in what these regions reveal about disease mechanisms. Researchers don’t yet know the specific function of every newly discovered locus, but the regions cluster around biological pathways that have long been suspected in Alzheimer’s pathology—immune system function, cholesterol and lipid metabolism, and the processing of amyloid and tau proteins. The 16 newly identified regions are particularly valuable because they suggest that previous estimates of genetic architecture were incomplete, and they may contain the next generation of drug targets.
Beyond the headline number of 91 loci, a separate genome-wide association study published in Nature Genetics examined neuropathology endophenotypes—the actual brain changes visible at autopsy—in 7,804 individuals who had donated their brains to research. This study identified three previously unknown genetic loci: COL4A1, LZTS1, and APOC2, each associated with the severity of amyloid plaques, tau tangles, or neurodegeneration visible in brain tissue. This approach provides a crucial connection that raw genetic association studies cannot: it links genetic variants directly to the physical brain pathology that causes cognitive decline. A limitation of this research is that it relied on autopsy data, meaning participants had to agree to brain donation and the study captured only those who had died, potentially missing genetic factors that influence disease course in living individuals who manage their symptoms successfully.
How Immune Cells and Lipid Metabolism Emerge as Key Players in Genetic Risk
The biological pathways underlying the 91 genetic loci point to immune system dysfunction as a central feature of genetic Alzheimer’s risk. Multiple genetic variants associated with disease affect genes expressed in microglia—the brain’s resident immune cells—suggesting that abnormal immune responses may contribute to accumulation of amyloid and tau proteins. Other pathways identified through these studies involve lipid metabolism, with genes affecting cholesterol processing and transport showing up repeatedly across the genetic landscape.
This convergence of different genetic variants onto a handful of biological pathways suggests these processes are not peripheral to Alzheimer’s but fundamental to how the disease develops in genetically susceptible individuals. The lipid metabolism pathway discovery carries particular clinical significance because it explains why some genetic variants influence amyloid deposition while others primarily affect cognitive decline independent of amyloid presence. APOE, the strongest known genetic risk factor for Alzheimer’s disease, works primarily through lipid metabolism and amyloid handling—people with the APOE-ε4 variant have approximately a threefold increased risk of developing Alzheimer’s disease, and this variant is present in roughly 15% of the general population but in a much higher proportion of those with disease. What makes the newer findings valuable is that they show amyloid and tau biology are not the only genetic pathways that matter; neuronal cell types show enrichment for genetic variants in ways never before demonstrated, suggesting that how neurons themselves function and survive may be genetically determined separately from how well immune cells manage protein buildup.
Understanding Polygenic Risk Scores—From Genetic Data to Individual Prediction
Polygenic risk scores represent an attempt to transform the 91 discovered genetic loci into a practical tool for assessing individual disease risk. Rather than asking whether a person carries one “bad” gene, polygenic scores sum up the cumulative effect of hundreds or thousands of genetic variants, with each variant weighted by its statistical contribution to disease risk. People with the highest polygenic scores have approximately twice the likelihood of developing severe Alzheimer’s-related brain pathology compared to those with average genetic risk. However, it’s important to recognize that this twofold increase in severity risk is not the same as a guarantee—many people with high genetic risk scores never develop cognitive symptoms, while some with average genetic risk do develop disease.
The heritability of Alzheimer’s disease—the proportion of disease variation attributable to genetic factors—is estimated at approximately 19%, meaning that genetic factors explain less than one-fifth of the variation in disease occurrence. The remaining disease risk comes from environmental exposures, lifestyle factors, vascular health, education, cognitive reserve, and likely many factors researchers have not yet identified. This is a crucial perspective for individuals who learn they have high genetic risk: the score provides information about probability, not destiny. Recent improvements in polygenic score accuracy have come from including more diverse ancestry groups in genetic studies, as variants affect disease risk differently depending on genetic background and environment. Polygenic scores developed using only European ancestry data performed poorly when applied to African Americans or other populations, but including African American research participants in study samples has dramatically improved prediction accuracy across populations.
The APOE Gene and Beyond—Why Some Genetic Risk Factors Matter More Than Others
The apolipoprotein E (APOE) gene stands out among the 91 genetic loci because of its unusually large effect on disease risk. The APOE-ε4 variant increases Alzheimer’s disease risk by more than threefold, making it the single most important genetic risk factor identified. By contrast, most of the other 90 loci have much smaller individual effects, typically increasing risk by 5-15% each. What researchers have learned from studying APOE is that this gene specifically influences amyloid accumulation in the brain—people with APOE-ε4 tend to accumulate amyloid plaques earlier and more extensively than those without this variant. However, amyloid accumulation alone does not cause dementia; many older adults with significant amyloid pathology remain cognitively normal, a phenomenon that has perplexed researchers for years.
The answer to this puzzle may lie in how the other 90 genetic loci function in combination with APOE and amyloid. Recent research suggests that while APOE-ε4 drives amyloid deposition, other genetic risk factors determine who among those with amyloid actually develops dementia symptoms. This distinction is crucial for understanding Alzheimer’s as a disease with multiple genetic components rather than a single genetic cause. A significant limitation in current knowledge is that these findings come predominantly from studies of people of European ancestry, and the exact role of some genetic variants in African American, Hispanic, or Asian populations remains unclear. As research expands to include more diverse populations, new risk variants and new mechanistic insights specific to particular ancestral groups continue to emerge, suggesting that genetic risk architecture is more complex than initially appreciated.
Multi-Ancestry Research—Moving Beyond European Ancestry Studies
For decades, genetic studies of Alzheimer’s disease relied overwhelmingly on participants of European ancestry, creating a scientific blind spot about how disease genetics operates in other populations. Genome-wide association studies of Alzheimer’s disease stratified by ancestry, sex, onset age, and APOE genotype have recently been conducted in African American participants, revealing novel risk loci that had been missed in previous European ancestry-only analyses. This work has practical implications: a polygenic risk score that works well in European ancestry populations may miss important risk factors in African Americans or provide inaccurate risk estimates.
For example, some genetic variants that increase disease risk in one population may have minimal effect in another, or vice versa, due to differences in allele frequency, linkage disequilibrium patterns, and gene-environment interactions. The expansion of genetic research to include non-European ancestry populations serves a dual purpose: it advances scientific knowledge about disease mechanisms while simultaneously addressing health disparities in dementia research and clinical care. When clinical polygenic scores are developed using only European ancestry data, they inadvertently create a system in which genetic risk assessment becomes less accurate for precisely those populations that have historically been underrepresented in medical research. Including African American, Hispanic, Asian, and other ancestry groups in large-scale GWAS studies improves polygenic score prediction for everyone, while also revealing genetic factors that are particularly important in specific populations.
Future Directions—From Genetic Discovery to Clinical Application
The identification of 91 genetic loci associated with Alzheimer’s disease is only the beginning of translating genetic knowledge into clinical practice. Researchers now face the challenge of understanding the function of these genetic variants—many fall outside protein-coding regions, suggesting they regulate gene expression rather than directly changing protein structure. Functional studies, where researchers experimentally test how variants affect biological processes, will likely reveal new drug targets in immune pathways, lipid metabolism, and neuronal function. Some companies are already beginning to develop drugs targeting variants in immune-related pathways identified through this type of genetic research.
As clinical application develops, the field faces important questions about how to use genetic information responsibly. Polygenic risk scores can identify people at higher genetic risk, but clinical trials will need to determine whether genetic risk information should guide treatment recommendations, screening intensity, or lifestyle interventions. The discovery that genetic risk operates through multiple distinct biological pathways suggests that future treatments may need to be personalized based on which genetic risk factors a particular person carries—a form of precision medicine that is still years away from clinical reality. The ongoing expansion of research to include diverse ancestry groups will be essential for ensuring that any precision medicine approaches developed in the next decade benefit all populations fairly.
Conclusion
Genome-wide studies have dramatically expanded our understanding of Alzheimer’s disease genetics, moving from rough estimates of 75-90 genetic risk loci to a map of 91 distinct regions, with 16 newly discovered. These findings reveal that Alzheimer’s disease risk is polygenic—determined by the cumulative effect of many genetic variants operating through multiple biological pathways including immune function, lipid metabolism, and amyloid and tau biology. The research demonstrates that genetic risk contributes approximately 19% of disease variation, with the other 81% influenced by lifestyle, environment, education, vascular health, and other factors individuals can influence.
For individuals concerned about Alzheimer’s disease risk, these genetic discoveries have both important limits and important promise. A high polygenic risk score indicates increased statistical likelihood of developing disease but not certainty, and genetic risk can be substantially modified through exercise, cognitive engagement, cardiovascular health management, and cognitive reserve building. Ongoing research will determine which genetic variants might predict response to emerging Alzheimer’s treatments, potentially enabling precision medicine approaches tailored to individual genetic profiles. The key next steps involve expanding genetic research to include all ancestry groups, understanding the biological function of newly identified genetic regions, and translating genetic discoveries into interventions that reduce dementia risk across all populations.
You Might Also Like
- Early-Onset Dementia Risk: The Everyday Habit Under New Scrutiny
- Dementia and Genetics: What New Alzheimer’s Studies Are Finding
- Lewy Body Dementia Symptoms That Are Often Missed Early
For more, see National Institute on Aging.
